Pharmacokinetic Evaluation by Modeling and Simulation Analysis of a Donepezil Patch Formulation in Healthy Male Volunteers

• Published in: Drug design, development and therapy Vol. 14; pp. 1729 - 1737
• Main Authors: Yoon, Seok Kyu, Bae, Kyun-Seop, Hong, Dong Hyun, Kim, Seong Su, Choi, Young Kweon, Lim, Hyeong-Seok
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2020; Dove; Dove Medical Press
• Subjects: Administration, Oral; Adult; Analysis; Biological Availability; Cholinesterase Inhibitors - administration & dosage; Cholinesterase Inhibitors - blood; Cholinesterase Inhibitors - pharmacokinetics; clinical trial simulation(s); clinical trial(s); Donepezil; Donepezil - administration & dosage; Donepezil - blood; Donepezil - pharmacokinetics; Dosage and administration; Drug Compounding; Healthy Volunteers; Humans; Male; Models, Biological; Monte Carlo Method; Original Research; pharmacokinetics; pharmacometrics; South Korea; pharmacokinetics; analysis; clinical trial simulation(s); pharmacometrics; clinical trial(s)
• ISSN: 1177-8881; 1177-8881
• DOI: 10.2147/dddt.s244957

This study characterized the pharmacokinetics (PKs) of a donepezil patch formulation currently under development, using mixed effect modeling analysis, and explored optimal patch dosing regimens in comparison with the donepezil oral formulation. PK data used in this analysis were from 60 healthy Korean male subjects participating in two Phase I studies, where subjects received single or multiple doses of donepezil of 43.75, 87.5, and 175 mg via patches, and 12 of them received a single oral dose of 10 mg of donepezil, followed by a single dose of donepezil via a patch. Donepezil PKs were analyzed by nonlinear mixed effect modeling using NONMEM software. A well-stirred model with two-compartment distribution and delayed absorption was chosen as the best model for the oral formulation. The PKs of donepezil after the patch applications were best described by a two-compartment linear model with zero-order absorption (D2) and absorption delay. The relative bioavailability (BA) of donepezil after the patch application compared with oral dosing was described to be affected by the duration of patch application. PK simulations based on the chosen PK models suggested that, overall, donepezil exposure in plasma is similar whether with 10 mg of oral donepezil every 24 h or a 175 mg patch every 72 h, and likewise with 5 mg of oral donepezil every 24 h or an 87.5 mg patch every 72 h.